{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:35:39Z","timestamp":1786649739897,"version":"build-2736575974"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:p>Current management of pediatric heart failure (HF) remains challenging. The emergence of sodium glucose cotransporter 2 inhibitors (SGLT2i) offers potential benefits beyond their traditional use in diabetes care. This review aims to provide a comprehensive perspective on the potential of SGLT2i to address pediatric HF. A literature search was conducted across PubMed\/MedLine, Scopus, Cochrane Library, and gray literature repositories. This review included studies on SGLT2i use in pediatric HF, focusing on patients aged 18 or younger. The quality of the studies was independently assessed by four reviewers, with discrepancies resolved by consensus. A narrative synthesis was conducted to evaluate the clinical outcomes reported across the included studies. The protocol was registered in the Prospective Register of Systematic Reviews (CRD420251051396). Five studies were included in the analysis. Studies have reported an increase in ejection fractions and a decrease in natriuretic peptide levels following treatment with SGLT2i. Echocardiographic findings generally suggested a positive impact on the severity of ventricular dilation and atrioventricular valve regurgitation. There were no significant changes in the hemodynamic status, liver function, blood glucose, and electrolyte levels; however, we observed a notable decrease in glomerular filtration rate, an increase in serum creatinine, an elevated risk of acute kidney injury, protein-losing enteropathy, persistent abdominal pain, and urinary tract infection. SGLT2i offers therapeutic promise in pediatric HF with an acceptable safety failure. Preliminary data support further investigations to guide clinical adoption.<\/jats:p>","DOI":"10.4103\/apc.apc_158_25","type":"journal-article","created":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T13:00:12Z","timestamp":1767272412000},"page":"380-387","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["New hope for young hearts: A systematic review of sodium glucose cotransporter 2 inhibitors in pediatric heart failure"],"prefix":"10.4103","volume":"18","author":[{"given":"Ghea","family":"Mangkuliguna","sequence":"first","affiliation":[{"name":"School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, North Jakarta, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. Wayan Andrew","family":"Handisurya","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Tarakan Regional General Hospital, Jakarta, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia","family":"Jahja","sequence":"additional","affiliation":[{"name":"School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, North Jakarta, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Adrianto","sequence":"additional","affiliation":[{"name":"School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, North Jakarta, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,1,1]]},"reference":[{"key":"R1-20260420","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.cardfail.2012.03.001","article-title":"Prevalence, morbidity, and mortality of heart failure-related hospitalizations in children in the United States: A population-based study","volume":"18","author":"Rossano","year":"2012","journal-title":"J Card Fail"},{"key":"R2-20260420","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1001\/jama.298.10.1171","article-title":"Carvedilol for children and adolescents with heart failure: A randomized controlled trial","volume":"298","author":"Shaddy","year":"2007","journal-title":"JAMA"},{"key":"R3-20260420","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"R4-20260420","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"R5-20260420","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jacc.2022.11.006","article-title":"Effect of dapagliflozin on health status in patients with preserved or mildly reduced ejection fraction","volume":"81","author":"Kosiborod","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"R6-20260420","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1161\/CIRCULATIONAHA.120.047480","article-title":"Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction: A prespecified analysis of DAPA-HF","volume":"142","author":"Docherty","year":"2020","journal-title":"Circulation"},{"key":"R7-20260420","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"R8-20260420","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s00246-022-02983-0","article-title":"Early clinical experience with dapagliflozin in children with heart failure","volume":"44","author":"Newland","year":"2023","journal-title":"Pediatr Cardiol"},{"key":"R9-20260420","article-title":"Dapagliflozin use in children with advanced heart failure undergoing heart transplantation: A matched case-control study","author":"Newland","year":"2024","journal-title":"Pediatr Cardiol"},{"key":"R10-20260420","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00246-023-03332-5","article-title":"Experience with SGLT2 inhibitors in patients with single ventricle congenital heart disease and fontan circulatory failure","volume":"46","author":"Konduri","year":"2025","journal-title":"Pediatr Cardiol"},{"key":"R11-20260420","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1016\/j.healun.2024.02.304","article-title":"SGLT2i use in pediatric heart failure: Multicenter study","volume":"43","author":"Butts","year":"2024","journal-title":"J Heart Lung Transplant"},{"key":"R12-20260420","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.33963\/v.phj.102194","article-title":"Treatment with dapagliflozin in pediatric patients with heart failure in four different etiologies: A case series","volume":"82","author":"Kurkiewicz-Sawczak","year":"2024","journal-title":"Kardiol Pol"},{"key":"R13-20260420","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R14-20260420","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: A state-of-the-art review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"key":"R15-20260420","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2337\/dc16-0330","article-title":"CV protection in the EMPA-REG OUTCOME trial: A \u201cthrifty substrate\u201d hypothesis","volume":"39","author":"Ferrannini","year":"2016","journal-title":"Diabetes Care"},{"key":"R16-20260420","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: Cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"R17-20260420","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1093\/eurheartj\/ehaa183","article-title":"Effects of dapagliflozin in DAPA-HF according to background heart failure therapy","volume":"41","author":"Docherty","year":"2020","journal-title":"Eur Heart J"},{"key":"R18-20260420","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1161\/CIRCULATIONAHA.122.060805","article-title":"SGLT2 inhibitors in heart failure: Targeted metabolomics and energetic metabolism","volume":"146","author":"Santos-Gallego","year":"2022","journal-title":"Circulation"},{"key":"R20-20260420","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1161\/CIRCULATIONAHA.118.035901","article-title":"Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function","volume":"138","author":"Neuen","year":"2018","journal-title":"Circulation"},{"key":"R21-20260420","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Annals of Pediatric Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/apc.apc_158_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:57:52Z","timestamp":1786647472000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/apc.apc_158_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/apc.apc_158_25","relation":{},"ISSN":["0974-2069","0974-5149"],"issn-type":[{"value":"0974-2069","type":"print"},{"value":"0974-5149","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"2025-06-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}